Legal & General Group
XLO icon

Legal & General Group’s Xilio Therapeutics XLO Stock Holding History

Legal & General Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$5K – 3674
2022
Q1 		$5K Hold
50
– – ﹤0.01% 3510
2021
Q4 		$11K Buy
+50
New +$11.9K ﹤0.01% 3447

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Legal & General Group's XLO Position: Q2 2022 in Review

Legal & General Group sold out of Xilio Therapeutics (XLO) in Q2 2022, closing a stake of 50 shares — an estimated $5K sold.

Legal & General Group first reported a position in XLO in Q4 2021 and held it in 2 quarters. The position peaked at $11K in Q4 2021. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2022.

  • Legal & General Group reported no remaining Xilio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 50 Xilio Therapeutics shares in Q2 2022, an estimated $5K.
  • Legal & General Group first reported a position in Xilio Therapeutics in Q4 2021 and held it in 2 quarters.
  • Legal & General Group's Xilio Therapeutics position peaked at $11K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.